Skip to main content

BRIEF RESEARCH REPORT article

Front. Bioeng. Biotechnol.
Sec. Bioprocess Engineering
Volume 12 - 2024 | doi: 10.3389/fbioe.2024.1505338

Repeated harvest enables efficient production of VSV-GP

Provisionally accepted
Rebecca Habisch Rebecca Habisch 1Peter Neubauer Peter Neubauer 2Jorge Soza Ried Jorge Soza Ried 1*Eva Puschmann Eva Puschmann 1*
  • 1 Boehringer Ingelheim, Viral Therapeutics Center, Ochsenhausen, Ochsenhausen, Germany
  • 2 Technical University of Berlin, Berlin, Brandenburg, Germany

The final, formatted version of the article will be published soon.

    Viral products keep gaining importance in multiple therapeutic fields. Considering the scale and production slot limitations, optimizing the outcome of every manufacturing batch is essential to minimize costs and make this therapeutic modality broadly available to patients. Most manufacturing processes for oncolytic viruses currently in clinical studies are based on a batch process. Here, we evaluated the benefits in terms of titer increase of a repeated harvest approach and compared it to the classical batch production process. While no effect on cell density was observed, the cumulated infectious titer following repeated harvest was over 400 times higher than the evaluated batch process yield. This shows that repeated harvests or perfusion have the potential to boost viral yields and should be considered when deciding on a process format for production.

    Keywords: VSV-GP, Oncolytic virus production, bioprocess development, Repeated-batch, perfusion (Min.5-Max. 8

    Received: 02 Oct 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 Habisch, Neubauer, Soza Ried and Puschmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jorge Soza Ried, Boehringer Ingelheim, Viral Therapeutics Center, Ochsenhausen, Ochsenhausen, Germany
    Eva Puschmann, Boehringer Ingelheim, Viral Therapeutics Center, Ochsenhausen, Ochsenhausen, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.